More Shionogi & Co., Ltd. news Shionogi & Co., Ltd.TSE: 4507 Positive Topline Results from Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome Followed by SOC in Patients with Invasive Aspergillosis Jun 18, 2026 · Issued by Shionogi & Co., Ltd. via TDnet As issuedPlain English Watch Shionogi & explain it↗Shionogi & Co Ltd (SGIOF) Q3 2024 Earnings Call · Replay · Jan 31, 2025Shionogi & Co., Ltd. (4507) Press ReleaseView Attachment Company analysis
